![](/images/graphics-bg.png)
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment
المؤلفون المشاركون
Granieri, E.
Fainardi, Enrico
Rizzo, Roberta
Elia, Francesca
Bellini, Tiziana
Bergamaschi, Roberto
Delbue, Serena
Castellazzi, Massimiliano
Franciotta, D.
Gastaldi, Matteo
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-05-26
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system.
Natalizumab, a humanized anti-α4 integrin monoclonal antibody, is a highly effective treatment approved for MS.
An association between MS and an exposure to Epstein-Barr Virus (EBV) sustained by the levels of antiviral capsid antigen (VCA) and anti-Epstein-Barr nuclear antigen-1 (EBNA-1) IgG has been described.
Our goal was to verify the utility of EBV-specific IgG as a marker in Natalizumab treated MS.
Twenty patients (17 female and 3 male) in treatment with Natalizumab were enrolled.
Serum levels of anti-VCA and anti-EBNA-1 IgG were determined and expressed as arbitrary units (AU) before treatment and every three months for 21 months of therapy.
Anti-VCA IgG levels were increased at the 15th month (235410 ± 196712 AU) comparing with the 3rd (98146 ± 47145 AU) and the 6th (109866 ± 52270 AU) months of therapy p<0.05.
No significant differences were found for serum anti-EBNA-1 IgG levels.
Our data indicate that a transient, self-limited, EBV reactivation can occur in MS during Natalizumab therapy but our results do not support the use of serum EBV-specific antibody levels as biomarkers for monitoring therapeutic response to Natalizumab in the course of MS.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Castellazzi, Massimiliano& Delbue, Serena& Elia, Francesca& Gastaldi, Matteo& Franciotta, D.& Rizzo, Roberta…[et al.]. 2015. Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment. Disease Markers،Vol. 2015, no. 2015, pp.1-5.
https://search.emarefa.net/detail/BIM-1061076
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Castellazzi, Massimiliano…[et al.]. Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment. Disease Markers No. 2015 (2015), pp.1-5.
https://search.emarefa.net/detail/BIM-1061076
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Castellazzi, Massimiliano& Delbue, Serena& Elia, Francesca& Gastaldi, Matteo& Franciotta, D.& Rizzo, Roberta…[et al.]. Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment. Disease Markers. 2015. Vol. 2015, no. 2015, pp.1-5.
https://search.emarefa.net/detail/BIM-1061076
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1061076
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)